Cell Culture Scale-Up
When culturing stem cells, "scale-up" can take on various meanings depending on your goals. Whether you want to increase the quantity or yield of your chosen cell type(s), move from traditional two-dimensional (2D) culture systems to three-dimensional (3D) platforms, or transition to large-scale clinical manufacturing, º£½ÇÆƽâ°æ Technologies can support you with tools, expertise, and guidance tailored to every aspect of scale-up.
Browse the resources below for insights on scaling up human pluripotent stem cells (hPSCs), immune cells, hematopoietic stem and progenitor cells (HSPCs), and other specialized cell types. Topics include maintaining characteristics like pluripotency and differentiation potential, meeting compliance regulations, optimizing cultures to achieve high yields, and adopting systems to mimic in vivo conditions for disease modeling, drug discovery, and therapeutic development.
On-Demand Ancillary Materials Course
In this self-paced, virtual course, you will learn how ancillary materials influence the safety, consistency, and scalability of cell and gene therapy manufacturing. Understanding these impacts is essential to successfully scaling up production while maintaining product quality and regulatory compliance.
Register Now >-
“Accelerating Stem Cell Treatments†Featuring Dr. Maria MillanOn this episode of the Stem Cell Podcast, Dr. Maria Millan from the California Institute for Regenerative Medicine (CIRM) talks about her transition from surgeon to stem cell specialist, how California culture has helped CIRM to thrive, and its role in training the next generation of stem cell scientists. -
Tools for Optimizing Human Immune Cell ResearchObtaining consistent and reliable results when culturing immune cells can be challenging. Watch this webinar to discover how to obtain high yields of functional T cells, NK cells, B cells, dendritic cells, and macrophages for your research applications. The speaker, Evan Karas, also explains how to expand primary T cells without feeders or serum. -
“Developing Regenerative Medicines†Featuring Dr. Stefan IrionOn this episode of the Stem Cell Podcast, Dr. Stefan Irion from BlueRock Therapeutics discusses the company’s Parkinson’s disease trial and the challenges of genetically manipulating stem cells.
